Breaking News, Collaborations & Alliances

Regeneron, Alnylam Enter Discovery Collaboration

To identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals have entered a collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) and potentially other related diseases.    The discovery collaboration is based on a new Regeneron publication in the New England Journal of Medicine identifying for the first time a variant in the HSD17B13 gene that is associated with reduced risk of chronic liver diseases. RNA interference (RNAi) therapeutics ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters